Abstract 930P
Background
Nodal involvement significantly influences prognostic outcomes in oral squamous cell carcinoma (OSCC). Current staging systems classify pathological extranodal extension (pENE) as N2a and N3b. This study assesses the prognostic efficacy of redefining nodal stages based on quantitative lymph node involvement.
Methods
A single centre retrospective analysis of 3864 patients with oral cancer from 2015 to 2023 was evaluated, and 825 patients with (pENE) OSCC patients were found. The final study analysis included 640 patients examining clinical and pathological variables influencing the DFS and OS. The primary outcome measures were disease-free survival (DFS) and overall survival (OS), analyzed through Cox regression and Kaplan-Meier survival curves.
Results
Of 640 patients, 79.4% were males with a median age of 48. 50% of patients had primary lesions in the buccal mucosa, and 46% had lesions on the tongue and floor of the mouth. Patients with ≤ 4 positive lymph nodes exhibited significantly better DFS (HR 0.53, 95% CI 0.4-0.6, p<0.001) and OS (HR 0.6, 95% CI 0.58-0.79, p<0.001) compared to those with four or more nodes. The mean DFS for patients with ≤ four nodes was 41.4 months, vs 20.5 months in the >4 group. Similarly, the mean OS was 62.3 months in the ≤ lymph node group versus 26.4 months in the >4 group. Multivariate analysis confirmed lymph node count as a robust predictor of survival, outperforming traditional ENE-based classification.
Conclusions
Extranodal extension is a bad prognostic factor in OSCC; however, the number of positive lymph nodes in patients with extranodal extension showed a significant difference in DFS and OS. A further classification in patients with ENE based on positive lymph nodes can give better prognostication; hence, it should be considered to refine the pathological nodal staging system for better prognostication.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
907P - Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Denis Soulieres
Session: Poster session 03
909P - Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Presenter: Alix Marhic
Session: Poster session 03
911P - Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Presenter: Xinrui Chen
Session: Poster session 03
912P - Selection of personalized salvage treatments in advanced refractory head and neck squamous cell carcinomas via multi-omics tumor profiling
Presenter: Ramin Ajami
Session: Poster session 03
913P - Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Presenter: Juan Carlos Redondo González
Session: Poster session 03
914P - The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites
Presenter: Juan Carlos Redondo González
Session: Poster session 03
915P - Longer OS and RFS for CD3high/PD-L1+ head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Simon Laban
Session: Poster session 03
916P - Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Presenter: Abhishek Aggarwal
Session: Poster session 03